Company has been invited by The National Association of People with AIDS (NAPWA) to present at its non-commercial satellite symposium: Research Advances from Therapeutic Vaccines and Other Based Therapies Community Forum on July 22, 2010 at the XVIII International AIDS Conference in Vienna, Austria.
“We are pleased that the NAPWA has invited us to participate in this important conference. We have a strong scientific research & development team that utilizes a scientific six-step program to make sure that our products are safe and effective,” commented Brad Pyatt, CEO of MusclePharm Corporation. “To be part of this conference is an important endorsement of our business model and product development process,” continued Brad Pyatt.
Mariel Selbovitz, MPH will be presenting on behalf of MusclePharm on emerging evidence that the Company’s RE-CON product has shown clinical attributes that dramatically address the involuntary weight loss and catabolic cachexia in HIV patients on HAART (highly active antiretroviral therapy). These patients are at risk for the pathogenesis, transmigration and proliferation of resistant profiles of minority subspecies, provoking increased ratios of adverse proinflammatory cytokine ratios that are inversely correlated, as afforded by peer-reviewed literature, with a clear etiological pathway of morbid disease progression.
Catabolic cachexia, also known as AIDS related wasting syndrome, has historically been a leading cause of characteristic disease progression in AIDS patients. Cachexia is difficult to treat and typical interventions do not consistently translate to sustainable clinical benefits. Additionally, prophylactic therapeutic nutritional supplementation has been identified as one of the most cost effective interventions to prevent predictable related disease progression.
New York and other state Medicaid programs, as well as AIDS drug assistance programs and nation-wide Veterans Administration therapeutic formularies, all recognize the value of therapeutic nutritional supplementation interventions for the treatment of catabolic cachexia, the prognostic markers of which are associated with loss of appetite, uncontrolled diarrhea, macro and micronutrient deficiencies, abnormal cytokine presentation, proinflammatory oxidative stress and decreased caloric intake.
Several reports of observed clinical improvement in U.S. AIDS patients in outpatient settings indicate that (RE-CON) in conjunction with Medicaid approved sources of whey protein and HMB intake have dramatically increased lean body mass in patients diagnosed with catabolic cachexia, with definitive correlations to the prevention of the onset of HIV drug resistance. Clinical studies to further examine this phenomenon are now being planned by leading clinicians and community advocates in multi-site trials across the U.S. and Europe. A proposal for the federal facilitation of these studies is being prepared for the Adult AIDS Clinical Trials Group at the National Institute of Allergy and Infectious and Diseases, National Institutes of Health.
